MAZZON, FEDERICO
MAZZON, FEDERICO
Universita' degli Studi di MILANO
Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD
2025 C. Rusconi, A. Barone, A. Visentin, B. Bianchi, V.R. Zilioli, A. Bernardelli, S. Iadecola, E. Olivari, F.G. Rossi, M. Gotti, C. Cecchetti, B. Puccini, S. Franceschetti, A. Molteni, S. Steffanoni, F. Marino, A. Vanazzi, A. Guidetti, M. Merli, F. Mazzon, A. Marchetti, A. Cellini, C. Muzi, R. Miceli, C. Visco, A. Re, P. Corradini
Immunomodulatory cytokines and clonal dynamics in low‐risk myelodysplastic syndromes patients treated with luspatercept
2023 B. Fattizzo, A. Marchetti, A. Zaninoni, M. Lionetti, M. Riva, L. Rizzo, L. Pettine, N. Galli, F. Mazzon, E. Fermo, A. Maeda, A. Marella, M.C. Da Vià, F. Passamonti, N. Bolli, W. Barcellini
Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an "Old-fashioned" Drug be Effective?
2023 M. Riva, A. Bosi, L. Rizzo, F. Mazzon, S. Ferrari, F. Lussana, L. Borin, A. Castelli, R. Cairoli, W. Barcellini, A. Molteni, B. Fattizzo
Switching to an alternative recombinant erythropoietin agent in patients with myelodysplastic syndromes : a second honeymoon?
2021 B. Fattizzo, L. Rizzo, J.A. Giannotta, F. Mazzon, N. Cecchi, C. Frangi, W. Barcellini, M. Riva